• Coya Therapeutics expects topline results from its fully enrolled, 137-patient ALSTARS Phase 2/3 trial of COYA 302 in ALS in early Q2 2027.
• Cash of $35.8 million as of September 30, 2026, supports operations into the second half of 2027, beyond the expected ALS readout.
• A Phase 2 trial of COYA 302 in frontotemporal dementia is expected to begin in 2027.
• Dr. Reddy's ALS partnership provides up to approximately $700 million in potential milestones, with royalties on net sales.
• Clinical development of COYA 303 in Alzheimer's disease depends on securing non-dilutive funding or a partnership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.